Merck has launched a website targeted at physicians and patients on biosimilar drugs. With Merck gets into the biosimilar market in a big way is this an attempt to quell the concern and does it matter since insurers are going to have a bigger say?
Biosimilars
POST SUMMARY: Biosimilars are possible thanks to the Affordable Care Act and the law’s promise to bring cheaper versions of expensive biotech drugs to the U.S. market. The biosimilar of Neupogen will save the U.S. health system more than $5.5 billion over the next decade, assuming a “conservative discount of 30 percent off the current brand price,” Express Scripts said